The Journey to Serve 1 Million Cancer Patients with Oncotype DX Tests
Making Cancer Care Smarter
As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ Genomic Intelligence Platform. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey—from diagnosis through treatment and ongoing cancer management-through a single, trusted source easily accessed via our secure web-based platform for physicians to interpret and share results with patients.
"With millions of cancer patients around the world, it is critical to be able to individualize care. Oncotype DX tests have paved the way for precision medicine by providing personalized information based on the unique biology of every cancer, and by enabling confident, individualized treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes," said Harold A. Burstein, M.D., Ph.D., medical oncologist at the Dana-Farber Cancer Institute.
The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions, helping to guide treatment decisions for more than 1 million cancer patients worldwide. The company's flagship product, the Oncotype DX Breast Recurrence Score test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
Launched recently, in collaboration with Epic Sciences, the Oncotype DX AR-V7 Nucleus Detect assay helps men with metastatic prostate cancer determine the most effective, life-sustaining therapy. Performed in Epic Science's CLIA-certified laboratory, the test detects the expression of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells.
The portfolio of Oncotype DX tests is supported by a significant amount of clinical evidence, including 125 clinical studies involving 140,000 patients and more than 150 journal publications. Recently, the landmark TAILORx trial was published. This trial used the Oncotype DX Breast Recurrence Score test to define, with precision, the individual benefit of chemotherapy for early-stage breast cancer patients.
Oncotype IQ Platform Evolution
Innovating with Best in Class Sample-to-Answer Solution Globally
Through an exclusive collaboration with Biocartis, Genomic Health is developing in vitro diagnostic (IVD) versions of the Oncotype DX Breast Recurrence Score test, Genomic Prostate Score test, and potentially additional cancer tests on the Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
The Road Ahead
Looking ahead, we will continue to expand our Oncotype IQ platform through internal development programs and strategic partnerships, all with the goal of making cancer care smarter.